Royal Bank of Canada Acquires 141,376 Shares of Novo Nordisk A/S $NVO

Royal Bank of Canada boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 3.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 4,527,779 shares of the company’s stock after buying an additional 141,376 shares during the period. Royal Bank of Canada’s holdings in Novo Nordisk A/S were worth $166,396,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Quotient Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after purchasing an additional 177 shares during the period. Certuity LLC boosted its position in shares of Novo Nordisk A/S by 3.6% during the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after buying an additional 177 shares during the period. Oakworth Capital Inc. boosted its position in shares of Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after buying an additional 182 shares during the period. True North Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after buying an additional 199 shares in the last quarter. Finally, Revolve Wealth Partners LLC grew its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Expanded Wegovy access: Novo Nordisk partnered with Crux to offer simpler benefit designs and more predictable pricing for U.S. employer health plans. The agreement could reduce affordability barriers and broaden access to Wegovy, supporting future prescription growth. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Positive Sentiment: Oral Wegovy opportunity: The European Commission’s approval of Novo’s once-daily oral Wegovy pill provides a new growth avenue in obesity treatment. Combined with the U.S. employer-access deal, the developments have encouraged optimism about wider GLP-1 adoption. Novo Nordisk Is Up After EU Wegovy Pill Approval And US Access Deal
• Positive Sentiment: Strong underlying product demand: Analysts expect Ozempic and Wegovy sales to be the primary focus of the upcoming second-quarter report, with oral launches and label expansions potentially supporting continued growth. Broader investor commentary also identifies Novo as a major beneficiary of the expanding GLP-1 market. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Neutral Sentiment: Results approaching: Investors are waiting for quarterly evidence that Ozempic and Wegovy sales can offset mounting competitive pressure. The earnings report may be a near-term catalyst, but expectations could also increase volatility if sales, pricing, or guidance disappoint. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Negative Sentiment: CagriSema litigation: A U.S. judge allowed parts of a shareholder lawsuit to proceed. Investors allege Novo misled them about a key CagriSema clinical trial, creating legal, reputational, and potential financial risks for the company’s next-generation obesity pipeline. Why Shareholders Are Suing Novo Nordisk Over CagriSema
• Negative Sentiment: Valuation and competition concerns: Commentary argues that much of Novo’s GLP-1 opportunity may already be reflected in the stock, while competitive pressure could limit upside and pricing power. Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk A/S Stock Performance

NVO opened at $51.55 on Friday. The business’s 50-day simple moving average is $46.87 and its 200 day simple moving average is $45.49. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market capitalization of $230.17 billion, a PE ratio of 12.10, a PEG ratio of 4.70 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.